2026 Q1 Portfolio Activity
In 2026 Q1, Crestline Management, L.P. maintained a portfolio of 3 distinct positions. The fund also reduced its exposure to SANA BIOTECHNOLOGY INC by 38.1%.
Position History
hover any row below to update
Loading…
Total Positions
3
Quarter
2026 Q1
Top Holding
DNLI (91.7%)
Top 10 Concentration
100.0%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-3 of 3
Crestline Management, L.P. Full Holdings List — 2026 Q1
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
DNLI
DENALI THERAPEU...
|
Healthcare | 91.74% | 87.02% |
#1
Prev: #1
|
6.0 |
—
|
-600,000 | -21.3% |
P
S
|
2,210,732 | $42,446,054 | 2017 Q4 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
SANA
SANA BIOTECHNOL...
|
Healthcare | 4.70% | 9.32% |
#2
Prev: #2
|
3.4 |
—
|
-465,201 | -38.1% |
P
S
|
755,736 | $2,176,520 | 2021 Q2 | 13F Filing | 2026-03-31 | 2026-05-15 | |||
|
EGHT
8X8 INC NEW
|
Technology | 3.56% | 3.66% |
#3
Prev: #3
|
2.9 |
—
|
270 | 0.0% |
P
S
|
990,850 | $1,644,811 | 2016 Q3 | 13F Filing | 2026-03-31 | 2026-05-15 |
Showing 1-3 of 3 holdings